Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited
Danish pharmaceutical company Novo Nordisk (NYSE: NVO) just made the headlines for something other than Ozempic. Well, sort of. One of the company's subsidiaries, Novo Holdings, is responsible for deploying capital in a mission-driven, efficient way to help broaden Novo Nordisk's reach.
Earlier this week, Novo Holdings announced it was acquiring for a total enterprise value of $16.5 billion. Let's break down the deal and analyze why this transaction could be a game changer for Novo Nordisk in the long run.
Catalent is a subcontractor for drug developers. Essentially, Catalent helps fulfill demand for treatments such as Ozempic and Wegovy at their various manufacturing facilities.
Source Fool.com
Catalent Inc. Stock
€52.32
-0.170%
The community is currently still undecided about Catalent Inc. with 2 Buy predictions and 0 Sell predictions.
As a result the target price of 55 € shows a slightly positive potential of 5.12% compared to the current price of 52.32 € for Catalent Inc..
